DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
41.1% reduction in heavy drinking days. NNT 4.3 (beats naltrexone NNT 7). Off-label but evidence-based. How to access, what dose works, and how it compares to traditional AUD meds.
Lancet May 2, 2026 — semaglutide beats traditional AUD meds in efficacy
Randomized trial of 386 adults with moderate-to-severe alcohol use disorder. Semaglutide 2.4mg weekly reduced heavy drinking days by 41.1% vs placebo at 26 weeks. NNT 4.3 — best efficacy of any pharmacotherapy currently studied for AUD.
GLP-1 receptors are expressed throughout the mesolimbic dopamine reward circuit — the same pathway alcohol hijacks to drive compulsive use. GLP-1 agonists dampen the dopamine spike from alcohol consumption, making drinking feel less rewarding. Animal models showed effect a decade before human trials caught up.
Mechanism extends beyond appetite: GLP-1 modulates impulsivity, food cravings, sweet preference, AND substance cravings. Patients on GLP-1 commonly report reduced interest in alcohol even when not actively trying to cut back.
| Medication | NNT | Heavy drinking reduction |
|---|---|---|
| Semaglutide 2.4mg | 4.3 | 41.1% |
| Naltrexone (oral) | 7 | 17% |
| Naltrexone (Vivitrol injection) | 8 | 25% |
| Acamprosate | 9 | 12% |
| Disulfiram | 14 | ~10% |
Yes — Lancet May 2026 randomized trial showed 41.1% reduction in heavy drinking days vs placebo. Number needed to treat (NNT) was 4.3, better than naltrexone (NNT 7) or acamprosate (NNT 9). Mechanism: GLP-1 modulates dopamine reward in mesolimbic circuits — same pathway alcohol hijacks.
Off-label. FDA hasn't approved semaglutide for AUD yet (trial-stage). Some addiction medicine specialists prescribe off-label citing the Lancet trial. Insurance won't cover for AUD indication alone — qualify via BMI/T2D pathway, document AUD as secondary indication.
Trial used semaglutide 2.4mg weekly (Wegovy dose, full titration). Lower doses (Ozempic 0.5-1.0mg) showed smaller effect. The dopamine-modulating effect appears dose-dependent.
Emerging evidence: nicotine cessation (modest effect), opioid use disorder (mixed), gambling (small open-label studies positive). Best evidence remains for AUD. Trials for stimulant use disorder and cannabis are ongoing 2026.
For many, yes — but craving intensity drops dramatically. Patients report drinks feeling "less rewarding" + reduced ability to drink quantities they previously enjoyed. Combine with traditional AUD treatment (therapy, peer support) for best outcomes.